ARS PHARMACEUTICALS INC
ARS Pharmaceuticals, trading as SPRY, is a clinical-stage biopharmaceutical company focused on developing treatments for respiratory and infectious diseases. As a smaller-cap, development-led company, its value is closely tied to the progress of its research pipeline, clinical trial results and any partnership or licensing deals. Investors should note that clinical-stage firms often face binary outcomes from trial readouts and regulatory reviews, which can produce substantial share-price volatility. The company's market capitalisation (~$978M) reflects expectations about future commercial potential but not guaranteed revenue. Because the business is development-focused, financing needs and dilution are possible as it advances programmes. This information is educational only and not personalised investment advice — consider your investment goals, risk tolerance and seek independent financial or tax advice before acting.
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying ARS Pharmaceuticals' stock due to significant potential for price growth.
Financial Health
ARS Pharmaceuticals is generating strong revenue and cash flow, indicating solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring SPRY
Beyond Opioids: The Race For New Painkillers
Vertex Pharmaceuticals has halted the development of its non-opioid painkiller, creating uncertainty but also a potential opening for competitors. This theme focuses on other pharmaceutical companies that could capture market share as they advance their own non-opioid treatments.
Published: August 5, 2025
Explore BasketNext-Generation Drug Delivery Systems
This carefully selected group of stocks represents innovative companies revolutionizing how medications are delivered to patients. Handpicked by our professional analysts, these firms are developing technologies that make treatments simpler, more effective, and user-friendly, creating meaningful investment potential in an evolving healthcare landscape.
Published: July 18, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage pipeline
Pipeline progress can change valuation quickly; promising readouts may boost prospects, while failures can reduce value.
Scientific catalysts
Trial results and regulatory milestones are likely to be major catalysts and can create sharp volatility; outcomes are uncertain.
Market potential
Respiratory and infectious disease markets can be substantial, but commercial success depends on approvals, reimbursement and execution.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
